Aravive Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) — Aravive, Inc. (Nasdaq:ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported financial results for the third quarter ended September 30, 2022 and provided corporate updates.
Related news for (ARAV)
- Aravive, Inc. to Delist from The Nasdaq Stock Market
- Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer
- Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC
- Aravive To Participate in Piper’s 34th Annual Healthcare Conference